Today, 19th June Joint Stock Company Grindeks will unveil the new Analytical Scaling Laboratory that is the only laboratory of this kind in the Baltic States and one of the some in Eastern Europe. Laboratory project was developed within five years time; 3.2 million lats were invested in the realisation of the project. Within the frameworks of the project additional fundings from EU European Regional Development Fund amounting 1.5 million lats. Resources attracted to the project are the largest funding of ERDF allocated to singe Latvian company. In March of this year Grindeks new Analytical Scaling Laboratory was certified accordingly to the requirements of Good Laboratory Practise that attests the compliance of this laboratory with the highest laboratory standarts of the world. „Realisation of this project strengthens positions of Grindeks as a pharmaceutical business inovative products leader in the Baltic States. Development of the laboratory will significantly increase competitiveness of Grindeks in the European and USA markets- we will have the ability to develop, as well as put into manufacturing new pharmaceutical product technologies and attract foreign clients in a faster pace than our competitors,” tells Chairman of the Board of JSC Grindeks Jānis Romanovskis. “Laboratory will secure stable growth of the sales of JSC Grindeks in the developed Western pharmaceutical markets, as well as the quality of the products respective to these high demanding markets. This will also be an advantage for the Latvian scientists - an ability to order synthesis of the new ingredients in this European class industrial laboratory,” emphasized Member of the Board of JSC Grindeks, Director of the Active Pharmaceutical Ingredients Business Unit Vitālijs Skrīvelis. Also Prime Minister of the Republic of Latvia Aigars Kalvītis and Minister of Welfare of the Republic of Latvia Vinets Veldre will attend this event. JSC Grindeks is the leading pharmaceutical company in the Baltic States, specializing in the manufacturing of heart and cardiovascular medications; CNS drugs and anti-cancer agents. Its concern consists of four subsidiary companies in Latvia, Estonia and Russia and seven representative offices. Production is being exported to 40 countries. Main markets - Baltic States, Russia, and CIS countries, Japan, Ireland, France, Netherlands and USA. Grindeks shares are listed in the Official list of Riga Stock Exchange. Additional information: Ilze Kreicmane Deputy Manager of the Communications Department JSC «Grindeks». Phone.: 7083336 Ilze.kreicmane@grindeks.lv Project is financed by the European Union European Regional Development Fund
JSC Grindeks opens the new Analytical Scaling Laboratory - first laboratory of this kind in the Baltic States
| Source: Grindeks